Of note, TIGIT (58), PDCD1 (59), HAVCR2 (60), CTLA4 (61) and BTLA (62) expression were reported to be predictive for favorable prognosis and immunotherapy response in melanoma. Here, HAVCR2 is linked to melanoma.